Medicine & healthcare

Study: Low Oxygen Levels Suppress Tumor Growth

Does starving tumors of oxygen stop cancer or does flooding them with oxygen fight it better?

FEB 12·Updated FEB 13

Study: Low Oxygen Levels Suppress Tumor Growth

Story

Above: The UCSF Medical Center in San Francisco, California, on Feb. 10, 2025. Image credit: Justin Sullivan/Getty Images

The Facts

Researchers at Gladstone Institutes, the University of California, San Francisco (UCSF) and the Arc Institute published a preprint study on Tuesday demonstrating that systemic hypoxia suppresses solid tumor growth across multiple cancer types and preclinical models.
Ayush Midha on X
Gladstone Institutes on X
Biorxiv
The study found that systemic hypoxia reduced tumor growth through suppression of de novo purine synthesis rather than through hypoglycemia, hypoinsulinemia or HIF activation, as revealed by metabolite profiling and stable isotope tracing experiments.
Biorxiv
Rapamycin News
Using the GENEVA platform, researchers implanted 20 human cancer cell lines into mice and exposed them to either normoxic (21% oxygen) or hypoxic (8-11% oxygen) conditions, finding that most cell lines exhibited reduced fitness under hypoxia, with some exceptions including melanoma and renal cell carcinomas.
Ayush Midha on X
News18
Biorxiv
The research showed that systemic hypoxia enhanced the tumor-suppressing effects of chemotherapy drug gemcitabine and anti-CTLA4 immunotherapy, with tumors not developing resistance to systemic hypoxia therapy over multiple passages.
Rapamycin News
Biorxiv
Scientists tested a small molecule called HypoxyStat that mimics systemic hypoxia by increasing hemoglobin's binding affinity for oxygen, demonstrating that pharmacological induction of hypoxia-like conditions could suppress tumor growth without requiring altitude or environmental chambers.
News18
Rapamycin News
The study noted that higher altitude counties in the U.S. generally have lower cancer mortality rates, with statistical analysis showing a significant negative correlation between elevation and age-adjusted pan-cancer mortality rates even after adjusting for income, obesity and diabetes.
Ayush Midha on X
News18
Biorxiv

Sources Split

LEFT

CENTER

RIGHT

ESTAB
CRIT

CENTER

PRO
ESTAB

The Spin

Techno-optimist narrative

Preclinical data suggests systemic hypoxia can selectively slow many tumors by shutting down Myc-driven purine synthesis, depriving cancer cells of DNA building blocks while sparing normal tissue. An “altitude-in-a-pill” drug reproduced these effects and enhanced chemo- and immunotherapy without resistance. If validated in humans, this metabolism-targeting adjunct could make frontline chemotherapy and checkpoint immunotherapy more consistent, deepen tumor responses, and lower the risk of treatment resistance.

Niko McCarty on X

Patrick Hsu on X

Isha Jain on X

Techno-skeptic narrative

The study’s hypoxia-as-therapy claim runs counter to decades of evidence linking tumor hypoxia to resistance and poor outcomes. Research on re-oxygenation, including hyperbaric oxygen, has shown improved chemo, radiation, and immunotherapy responses by enhancing drug delivery, DNA damage, and immune activity. The preclinical results are intriguing, but model constraints, mixed tumor responses, and lack of human data make sweeping therapeutic conclusions premature.

Sciencedirect